T
UTHR icon

Tidemark’s United Therapeutics UTHR Stock Holding History

Tidemark’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.1K Hold
50
– – 0.01% 378
2026
Q1 		$29.6K Hold
50
– – 0.01% 323
2025
Q4 		$24.4K Hold
50
– – 0.01% 314
2025
Q3 		$21K Sell
50
-30
-38% -$10.1K 0.01% 353
2025
Q2 		$23K Buy
80
+63
+371% +$18.8K 0.01% 347
2025
Q1 		$5.24K Buy
+17
New +$5.83K ﹤0.01% 512

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Tidemark's UTHR Position: Q2 2026 in Review

Tidemark held its United Therapeutics (UTHR) position steady in Q2 2026 at 50 shares worth $27.1K. The position accounts for 0.01% of the portfolio, ranked #378.

Tidemark first reported a position in UTHR in Q1 2025 and has held it in 6 quarters since. The position peaked at $29.6K in Q1 2026. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Tidemark held 50 shares of United Therapeutics worth $27.1K as of Q2 2026.
  • Tidemark left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up 0.01% of Tidemark's portfolio in Q2 2026, its #378 holding.
  • Tidemark first reported a position in United Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Tidemark's United Therapeutics position peaked at $29.6K in Q1 2026.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Tidemark's 13F filing for Q2 2026, filed 10 Aug 2026.